secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-095766
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Q2 net loss $18.8M; $220.4M cash; ACR-368 Phase 2 shows 50% ORR
-----------------------------------------------------------------------

- Net loss of $18.8M vs $13.9M YoY; R&D expenses $15.0M, G&A $6.4M.
- Cash, equivalents and marketable securities $220.4M expected to fund into H2 2026.
- ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive gynecological cancer patients.
- ACR-2316 WEE1/PKMYT1 inhibitor Phase 1 on track to start 4Q 2024.
- Raised $130M in oversubscribed private placement financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024095766/0000950170-24-095766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024095766/acrv-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer